Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML
A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (Omacetaxine Mepesuccinate) in the Treatment of Patients With Chronic Myeloid Leukemia (CML) Who Have Failed or Are Intolerant to Tyrosine Kinase Inhibitor Therapy
Status: Enrolling
Updated:  6/27/2014
Teva Investigational Site
mi
from
Seattle, WA
Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML
A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (Omacetaxine Mepesuccinate) in the Treatment of Patients With Chronic Myeloid Leukemia (CML) Who Have Failed or Are Intolerant to Tyrosine Kinase Inhibitor Therapy
Status: Enrolling
Updated: 6/27/2014
Teva Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML
A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (Omacetaxine Mepesuccinate) in the Treatment of Patients With Chronic Myeloid Leukemia (CML) Who Have Failed or Are Intolerant to Tyrosine Kinase Inhibitor Therapy
Status: Enrolling
Updated:  6/27/2014
Teva Investigational Site 11121
mi
from
Montreal,
Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML
A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (Omacetaxine Mepesuccinate) in the Treatment of Patients With Chronic Myeloid Leukemia (CML) Who Have Failed or Are Intolerant to Tyrosine Kinase Inhibitor Therapy
Status: Enrolling
Updated: 6/27/2014
Teva Investigational Site 11121
mi
from
Montreal,
Click here to add this to my saved trials
Engraftment Syndrome After Autologous Stem Cell Transplant: Retrospective Review in Patients With Multiple Myeloma
Engraftment Syndrome After Autologous Stem Cell Transplant: Retrospective Review in Patients With Multiple Myeloma
Status: Enrolling
Updated:  8/19/2014
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Engraftment Syndrome After Autologous Stem Cell Transplant: Retrospective Review in Patients With Multiple Myeloma
Engraftment Syndrome After Autologous Stem Cell Transplant: Retrospective Review in Patients With Multiple Myeloma
Status: Enrolling
Updated: 8/19/2014
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Observational Study Evaluating the Potential Impact of Procalcitonin Testing on Care of Stemcell Transplant Recipients
Observational Study Evaluating the Potential Impact of Procalcitonin Testing on Care of Stemcell Transplant Recipients and Its Performance as an Adjunct in the Diagnosis and Prognostication of Infectious Processes
Status: Enrolling
Updated:  8/19/2014
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Observational Study Evaluating the Potential Impact of Procalcitonin Testing on Care of Stemcell Transplant Recipients
Observational Study Evaluating the Potential Impact of Procalcitonin Testing on Care of Stemcell Transplant Recipients and Its Performance as an Adjunct in the Diagnosis and Prognostication of Infectious Processes
Status: Enrolling
Updated: 8/19/2014
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis
MOLECULAR TESTING OF CANCER BY INTEGRATED GENOMIC, TRANSCRIPTOMIC, AND PROTEOMIC ANALYSIS
Status: Enrolling
Updated:  8/26/2014
Rhode Island Comprehensive Cancer Center at East Greenwich
mi
from
East Greenwich, RI
Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis
MOLECULAR TESTING OF CANCER BY INTEGRATED GENOMIC, TRANSCRIPTOMIC, AND PROTEOMIC ANALYSIS
Status: Enrolling
Updated: 8/26/2014
Rhode Island Comprehensive Cancer Center at East Greenwich
mi
from
East Greenwich, RI
Click here to add this to my saved trials
Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis
MOLECULAR TESTING OF CANCER BY INTEGRATED GENOMIC, TRANSCRIPTOMIC, AND PROTEOMIC ANALYSIS
Status: Enrolling
Updated:  8/26/2014
Rhode Island Hospital
mi
from
Providence, RI
Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis
MOLECULAR TESTING OF CANCER BY INTEGRATED GENOMIC, TRANSCRIPTOMIC, AND PROTEOMIC ANALYSIS
Status: Enrolling
Updated: 8/26/2014
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis
MOLECULAR TESTING OF CANCER BY INTEGRATED GENOMIC, TRANSCRIPTOMIC, AND PROTEOMIC ANALYSIS
Status: Enrolling
Updated:  8/26/2014
Miriam Hospital
mi
from
Providence, RI
Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis
MOLECULAR TESTING OF CANCER BY INTEGRATED GENOMIC, TRANSCRIPTOMIC, AND PROTEOMIC ANALYSIS
Status: Enrolling
Updated: 8/26/2014
Miriam Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
Phase I/II Study of Ublituximab in Combination With Lenalidomide (Revlimid®) in Patients With B-Cell Lymphoid Malignancies Who Have Relapsed or Are Refractory After CD20 Directed Antibody Therapy
Status: Enrolling
Updated:  10/9/2014
TG Therapeutics Investigational Trial Site
mi
from
Huntsville, AL
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
Phase I/II Study of Ublituximab in Combination With Lenalidomide (Revlimid®) in Patients With B-Cell Lymphoid Malignancies Who Have Relapsed or Are Refractory After CD20 Directed Antibody Therapy
Status: Enrolling
Updated: 10/9/2014
TG Therapeutics Investigational Trial Site
mi
from
Huntsville, AL
Click here to add this to my saved trials
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
Phase I/II Study of Ublituximab in Combination With Lenalidomide (Revlimid®) in Patients With B-Cell Lymphoid Malignancies Who Have Relapsed or Are Refractory After CD20 Directed Antibody Therapy
Status: Enrolling
Updated:  10/9/2014
TG Therapeutics Investigational Trial Site
mi
from
Bethesda, MD
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
Phase I/II Study of Ublituximab in Combination With Lenalidomide (Revlimid®) in Patients With B-Cell Lymphoid Malignancies Who Have Relapsed or Are Refractory After CD20 Directed Antibody Therapy
Status: Enrolling
Updated: 10/9/2014
TG Therapeutics Investigational Trial Site
mi
from
Bethesda, MD
Click here to add this to my saved trials
Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
Early Post-transplant Contrast-enhanced Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated:  10/14/2014
Washington University School of Medicine
mi
from
Saint Louis, MO
Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
Early Post-transplant Contrast-enhanced Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation
Status: Enrolling
Updated: 10/14/2014
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Global Imatinib and Nilotinib Pregnancy Exposure Registry
A Global Imatinib and Nilotinib Pregnancy Exposure Registry A Post-Authorisation Safety Study (PASS)
Status: Enrolling
Updated:  10/19/2014
INC Research
mi
from
Wilmington, NC
A Global Imatinib and Nilotinib Pregnancy Exposure Registry
A Global Imatinib and Nilotinib Pregnancy Exposure Registry A Post-Authorisation Safety Study (PASS)
Status: Enrolling
Updated: 10/19/2014
INC Research
mi
from
Wilmington, NC
Click here to add this to my saved trials
Dietary and Exercise Interventions in Preventing Cardiovascular Disease in Younger Survivors of Leukemia, Lymphoma, or Brain Tumors
Effect of Non-Pharmacologic Interventions on Risk Factors of Cardiovascular Disease in Survivors of Childhood Leukemia, Lymphoma and Brain Tumor
Status: Enrolling
Updated:  12/2/2014
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Dietary and Exercise Interventions in Preventing Cardiovascular Disease in Younger Survivors of Leukemia, Lymphoma, or Brain Tumors
Effect of Non-Pharmacologic Interventions on Risk Factors of Cardiovascular Disease in Survivors of Childhood Leukemia, Lymphoma and Brain Tumor
Status: Enrolling
Updated: 12/2/2014
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias
Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias
Status: Enrolling
Updated:  12/4/2014
Penn State Hershey Cancer Institute
mi
from
Hershey, PA
Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias
Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias
Status: Enrolling
Updated: 12/4/2014
Penn State Hershey Cancer Institute
mi
from
Hershey, PA
Click here to add this to my saved trials
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated:  12/18/2014
GSK Investigational Site
mi
from
Phoenix, AZ
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated: 12/18/2014
GSK Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated:  12/18/2014
GSK Investigational Site
mi
from
Hot Springs, AR
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated: 12/18/2014
GSK Investigational Site
mi
from
Hot Springs, AR
Click here to add this to my saved trials
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated:  12/18/2014
GSK Investigational Site
mi
from
Jonesboro, AR
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated: 12/18/2014
GSK Investigational Site
mi
from
Jonesboro, AR
Click here to add this to my saved trials
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated:  12/18/2014
GSK Investigational Site
mi
from
Los Angeles, CA
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated: 12/18/2014
GSK Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated:  12/18/2014
GSK Investigational Site
mi
from
Stanford, CA
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated: 12/18/2014
GSK Investigational Site
mi
from
Stanford, CA
Click here to add this to my saved trials
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated:  12/18/2014
GSK Investigational Site
mi
from
Jacksonville, FL
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated: 12/18/2014
GSK Investigational Site
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated:  12/18/2014
GSK Investigational Site
mi
from
Orlando, FL
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated: 12/18/2014
GSK Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated:  12/18/2014
GSK Investigational Site
mi
from
West Palm Beach, FL
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated: 12/18/2014
GSK Investigational Site
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated:  12/18/2014
GSK Investigational Site
mi
from
Augusta, GA
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated: 12/18/2014
GSK Investigational Site
mi
from
Augusta, GA
Click here to add this to my saved trials
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated:  12/18/2014
GSK Investigational Site
mi
from
Baltimore, MD
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated: 12/18/2014
GSK Investigational Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated:  12/18/2014
GSK Investigational Site
mi
from
Boston, MA
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated: 12/18/2014
GSK Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated:  12/18/2014
GSK Investigational Site
mi
from
Kansas City, MO
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated: 12/18/2014
GSK Investigational Site
mi
from
Kansas City, MO
Click here to add this to my saved trials
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated:  12/18/2014
GSK Investigational Site
mi
from
Hackensack, NJ
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated: 12/18/2014
GSK Investigational Site
mi
from
Hackensack, NJ
Click here to add this to my saved trials
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated:  12/18/2014
GSK Investigational Site
mi
from
Voorhees, NJ
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated: 12/18/2014
GSK Investigational Site
mi
from
Voorhees, NJ
Click here to add this to my saved trials
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated:  12/18/2014
GSK Investigational Site
mi
from
Bornx, NY
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated: 12/18/2014
GSK Investigational Site
mi
from
Bornx, NY
Click here to add this to my saved trials
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated:  12/18/2014
GSK Investigational Site
mi
from
Philadelphia, PA
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated: 12/18/2014
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated:  12/18/2014
GSK Investigational Site
mi
from
Seattle, WA
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated: 12/18/2014
GSK Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated:  12/18/2014
GSK Investigational Site
mi
from
Milwaukee, WI
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: Open-label, Part 2: Randomized, Double-blind, Part 3: Extension)
Status: Enrolling
Updated: 12/18/2014
GSK Investigational Site
mi
from
Milwaukee, WI
Click here to add this to my saved trials
FLT-PET Imaging for MDS
A Pilot Study for Using 18F-FLT PET Imaging To Assess Response In Patients With Myelodysplastic Syndrome (MDS) Being Treated With 5-azacitidine
Status: Enrolling
Updated:  12/23/2014
University of Wisconsin
mi
from
Madison, WI
FLT-PET Imaging for MDS
A Pilot Study for Using 18F-FLT PET Imaging To Assess Response In Patients With Myelodysplastic Syndrome (MDS) Being Treated With 5-azacitidine
Status: Enrolling
Updated: 12/23/2014
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
A Phase 1/2a Dose Escalation Study of PVX-410, a Multi-Peptide Cancer Vaccine, in Patients With Smoldering Multiple Myeloma
Status: Enrolling
Updated:  12/30/2014
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
A Phase 1/2a Dose Escalation Study of PVX-410, a Multi-Peptide Cancer Vaccine, in Patients With Smoldering Multiple Myeloma
Status: Enrolling
Updated: 12/30/2014
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
A Phase 1/2a Dose Escalation Study of PVX-410, a Multi-Peptide Cancer Vaccine, in Patients With Smoldering Multiple Myeloma
Status: Enrolling
Updated:  12/30/2014
Illinois Cancer Specialists
mi
from
Niles, IL
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
A Phase 1/2a Dose Escalation Study of PVX-410, a Multi-Peptide Cancer Vaccine, in Patients With Smoldering Multiple Myeloma
Status: Enrolling
Updated: 12/30/2014
Illinois Cancer Specialists
mi
from
Niles, IL
Click here to add this to my saved trials
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
A Phase 1/2a Dose Escalation Study of PVX-410, a Multi-Peptide Cancer Vaccine, in Patients With Smoldering Multiple Myeloma
Status: Enrolling
Updated:  12/30/2014
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
A Phase 1/2a Dose Escalation Study of PVX-410, a Multi-Peptide Cancer Vaccine, in Patients With Smoldering Multiple Myeloma
Status: Enrolling
Updated: 12/30/2014
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
A Phase 1/2a Dose Escalation Study of PVX-410, a Multi-Peptide Cancer Vaccine, in Patients With Smoldering Multiple Myeloma
Status: Enrolling
Updated:  12/30/2014
Dana-Farber Cancer Institute
mi
from
Boston, MA
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
A Phase 1/2a Dose Escalation Study of PVX-410, a Multi-Peptide Cancer Vaccine, in Patients With Smoldering Multiple Myeloma
Status: Enrolling
Updated: 12/30/2014
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
A Phase 1/2a Dose Escalation Study of PVX-410, a Multi-Peptide Cancer Vaccine, in Patients With Smoldering Multiple Myeloma
Status: Enrolling
Updated:  12/30/2014
Massachusetts General Hospital
mi
from
Boston, MA
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
A Phase 1/2a Dose Escalation Study of PVX-410, a Multi-Peptide Cancer Vaccine, in Patients With Smoldering Multiple Myeloma
Status: Enrolling
Updated: 12/30/2014
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
A Phase 1/2a Dose Escalation Study of PVX-410, a Multi-Peptide Cancer Vaccine, in Patients With Smoldering Multiple Myeloma
Status: Enrolling
Updated:  12/30/2014
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
A Phase 1/2a Dose Escalation Study of PVX-410, a Multi-Peptide Cancer Vaccine, in Patients With Smoldering Multiple Myeloma
Status: Enrolling
Updated: 12/30/2014
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Pilot Study of ODSH in Acute Myeloid Leukemia
A Pilot Study to Evaluate the Safety and Preliminary Evidence of an Effect of ODSH (2 O, 3-O Desulfated Heparin) in Accelerating Platelet Recovery in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia
Status: Enrolling
Updated:  2/12/2015
Georgia Regents University Augusta - Div. of Hematology/Oncology - BMT
mi
from
Agusta, GA
A Pilot Study of ODSH in Acute Myeloid Leukemia
A Pilot Study to Evaluate the Safety and Preliminary Evidence of an Effect of ODSH (2 O, 3-O Desulfated Heparin) in Accelerating Platelet Recovery in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia
Status: Enrolling
Updated: 2/12/2015
Georgia Regents University Augusta - Div. of Hematology/Oncology - BMT
mi
from
Agusta, GA
Click here to add this to my saved trials
A Pilot Study of ODSH in Acute Myeloid Leukemia
A Pilot Study to Evaluate the Safety and Preliminary Evidence of an Effect of ODSH (2 O, 3-O Desulfated Heparin) in Accelerating Platelet Recovery in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia
Status: Enrolling
Updated:  2/12/2015
Medical University of South Carolina
mi
from
Charleston, SC
A Pilot Study of ODSH in Acute Myeloid Leukemia
A Pilot Study to Evaluate the Safety and Preliminary Evidence of an Effect of ODSH (2 O, 3-O Desulfated Heparin) in Accelerating Platelet Recovery in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia
Status: Enrolling
Updated: 2/12/2015
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
A Pilot Study of ODSH in Acute Myeloid Leukemia
A Pilot Study to Evaluate the Safety and Preliminary Evidence of an Effect of ODSH (2 O, 3-O Desulfated Heparin) in Accelerating Platelet Recovery in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia
Status: Enrolling
Updated:  2/12/2015
University of Utah Huntsman Cancer Institute - Div. of Hematology & Hematologic Malignncies
mi
from
Salt Lake City, UT
A Pilot Study of ODSH in Acute Myeloid Leukemia
A Pilot Study to Evaluate the Safety and Preliminary Evidence of an Effect of ODSH (2 O, 3-O Desulfated Heparin) in Accelerating Platelet Recovery in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia
Status: Enrolling
Updated: 2/12/2015
University of Utah Huntsman Cancer Institute - Div. of Hematology & Hematologic Malignncies
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Pilot Study of ODSH in Acute Myeloid Leukemia
A Pilot Study to Evaluate the Safety and Preliminary Evidence of an Effect of ODSH (2 O, 3-O Desulfated Heparin) in Accelerating Platelet Recovery in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia
Status: Enrolling
Updated:  2/12/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
A Pilot Study of ODSH in Acute Myeloid Leukemia
A Pilot Study to Evaluate the Safety and Preliminary Evidence of an Effect of ODSH (2 O, 3-O Desulfated Heparin) in Accelerating Platelet Recovery in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia
Status: Enrolling
Updated: 2/12/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment
A Pilot Study to Determine the Safety and Efficacy of Using Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment
Status: Enrolling
Updated:  2/13/2015
University of Kansas Medical Center
mi
from
Kansas City, KA
Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment
A Pilot Study to Determine the Safety and Efficacy of Using Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment
Status: Enrolling
Updated: 2/13/2015
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)
The ReTreatment Trial: A Phase II, Open-label, Single-arm Study of Re-treating Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event.
Status: Enrolling
Updated:  2/18/2015
Birmingham Hematology/Oncology SC - INC424A2407
mi
from
Birmingham, AL
A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)
The ReTreatment Trial: A Phase II, Open-label, Single-arm Study of Re-treating Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event.
Status: Enrolling
Updated: 2/18/2015
Birmingham Hematology/Oncology SC - INC424A2407
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)
The ReTreatment Trial: A Phase II, Open-label, Single-arm Study of Re-treating Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event.
Status: Enrolling
Updated:  2/18/2015
Edward H. Kaplan, MD and Associates SC - INC424A2407
mi
from
Skokie, IL
A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)
The ReTreatment Trial: A Phase II, Open-label, Single-arm Study of Re-treating Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event.
Status: Enrolling
Updated: 2/18/2015
Edward H. Kaplan, MD and Associates SC - INC424A2407
mi
from
Skokie, IL
Click here to add this to my saved trials
A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)
The ReTreatment Trial: A Phase II, Open-label, Single-arm Study of Re-treating Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event.
Status: Enrolling
Updated:  2/18/2015
University of Minnesota SC - INC424A2407
mi
from
Minneapolis, MN
A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)
The ReTreatment Trial: A Phase II, Open-label, Single-arm Study of Re-treating Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event.
Status: Enrolling
Updated: 2/18/2015
University of Minnesota SC - INC424A2407
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)
The ReTreatment Trial: A Phase II, Open-label, Single-arm Study of Re-treating Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event.
Status: Enrolling
Updated:  2/18/2015
University of Cincinnati Medical Center SC - INC424A2407
mi
from
Cincinnati, OH
A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)
The ReTreatment Trial: A Phase II, Open-label, Single-arm Study of Re-treating Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event.
Status: Enrolling
Updated: 2/18/2015
University of Cincinnati Medical Center SC - INC424A2407
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)
The ReTreatment Trial: A Phase II, Open-label, Single-arm Study of Re-treating Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event.
Status: Enrolling
Updated:  2/18/2015
University of Texas/MD Anderson Cancer Center Dept of MD Anderson (5)
mi
from
Houston, TX
A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)
The ReTreatment Trial: A Phase II, Open-label, Single-arm Study of Re-treating Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event.
Status: Enrolling
Updated: 2/18/2015
University of Texas/MD Anderson Cancer Center Dept of MD Anderson (5)
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias
A Phase I Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, a Hypoxia-Activated Prodrug, in Patients With Advanced Leukemias
Status: Enrolling
Updated:  5/5/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias
A Phase I Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, a Hypoxia-Activated Prodrug, in Patients With Advanced Leukemias
Status: Enrolling
Updated: 5/5/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
CNDO-109-AANK for AML in First Complete Remission (CR1)
A Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Patients With High Risk Acute Myeloid Leukemia in First Complete Remission (CR1)
Status: Enrolling
Updated:  5/5/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
CNDO-109-AANK for AML in First Complete Remission (CR1)
A Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Patients With High Risk Acute Myeloid Leukemia in First Complete Remission (CR1)
Status: Enrolling
Updated: 5/5/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials